CClinicalTrials.gg
CompletedNCT05245630Updated Feb 18, 2022

Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy

An observational study in Lung Cancer, Lung Diseases and Adenocarcinoma of Lung, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Completed at 1 site in India. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
59
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with suspicious lung lesions were undertaken for PET/CT directed under CT fluoroscopy lung biopsy or robotic-assisted biopsy. The biopsy planning including patient positioning was done after F18-FDG PET/CT whole body or regional imaging of the patient. Written consent was obtained and the patient will be prepared for the biopsy. Lung biopsies were done using a semi-automatic biopsy gun under the imaging guidance (PET fused CT fluoroscopy) following aseptic precautions. Follow-up CT scans were taken post-biopsy. The time consumed for the procedure, radiation exposure to the interventionist, complications and diagnostic yield in both the arms were compared.

Read the detailed description

Patients with clinical suspicion of lung lesions were recruited for FDG PET/CT. Based on the PET/CT findings and clinical details a PET/CT guided biopsy was planned. The patients were assigned to the two arms. In the first arm, participants underwent a robotic-assisted biopsy. In the second arm, participants underwent PET/CT-directed CT fluoroscopy-guided lung biopsy. The biopsy planning including patient positioning was done after F18-FDG PET/CT whole body or regional imaging of the patient. Written consent was obtained and the patient will be prepared for the biopsy. Lung biopsies were done using a semi-automatic biopsy gun under the imaging guidance (PET fused CT fluoroscopy) following aseptic precautions. Follow-up CT scans were taken post-biopsy. The time consumed for the procedure, radiation exposure to the interventionist, complications and diagnostic yield in both the arms were compared.

02

Conditions studied

  • Lung Cancer
  • Lung Diseases
  • Adenocarcinoma of Lung
03

In context

Adenocarcinoma of Lung

303 studies on the registry are indexed under Adenocarcinoma of Lung; 78 are open to participants now.

This study's enrollment of 59 is below the median of 200 across 80 observational studies indexed under Adenocarcinoma of Lung.

Browse Adenocarcinoma of Lung studies →

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 290 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The participants attending the pulmonary medicine department with clinical suspicion of lung lesions were referred to the Department of Nuclear Medicine for lung biopsies were recruited for the study. The participants were randomly assigned to either of the two intervention arms. Baseline heart rate, blood pressure, oxygen saturation and respiratory system examination were done for all the participants included in the study.

Inclusion criteria

  1. Age >/= 18 years
  2. FDG avid amenable lung lesion
  3. INR \< 1.2 and Platelet counts > 80,000/mm3

Exclusion criteria

Exclusion Criteria:

  1. Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by INR ≥ 1.2 and Platelet counts ≤ 80,000/mm3
  2. Participants who refuse to provide the written informed consent
  3. Signs of hypoperfusion like cyanosis, hypotension etc.
  4. Presence of hypoxemia (SpO2 \< 95% -measured in a pulse oximeter)
  5. Pregnant/Lactating females participants
  6. Non-cooperative participants
  7. Inaccessible lesions (based on the decision made on pre-biopsy planning)
  8. CoVID-19 positive participants
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
59 participants (actual)
Patient registry
No

Groups and cohorts

  • Robotic arm assisted PET/CT guided biopsy

    In this group, participants were recruited for robotic-assisted PET/CT guided biopsy from the FDG avid lung lesions. biopsies were done using an automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) to guide the needle for biopsy. It is a robotic arm with a four-ax guide arm and a planning console. Pre-interventional fused PET/CT images from Biograph mCT 16 scanner were sent via LAN cable to the device (MAXIO-EX) console.

    Procedure: Robotic arm assisted PET/CT guided biopsy · Procedure: PET fused CT-Fluoroscopy guided biopsy

  • PET fused CT-Fluoroscopy guided biopsy

    In this group, participants were recruited for PET fused CT-Fluoroscopy guided biopsy from the FDG avid lung lesions. A biopsy needle was placed to the target lesion on PET/CT under CT fluoroscopy

    Procedure: Robotic arm assisted PET/CT guided biopsy · Procedure: PET fused CT-Fluoroscopy guided biopsy

Interventions

  • ProcedureRobotic arm assisted PET/CT guided biopsy

    After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer. An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy. Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device. After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun. A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications. Complications during the procedure were noted, and immediate management was done.

  • ProcedurePET fused CT-Fluoroscopy guided biopsy

    CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion

06

What researchers measure

Primary outcomes

  1. To compare the accuracy ( in percentage) of trans-thoracic percutaneous PET fused CT-fluoroscopy guided lung biopsy and automated robotic arm assisted PET/CT guided lung biopsy

    Histology reports of the biopsies were recorded and the mutation analysis, Adequacy of the sample was decided by the pathologist who received the sample and when inadequate, we were notified accordingly by the Department of Pathology. The histopathological results were analyzed. True positive, True negative False-positive and False-negative were calculated for both the groups. The diagnostic accuracy in percentage for both arms will be calculated and compared.

    Time frame: three months

Secondary outcomes

  1. To compare the radiation exposure and complication in the both arms

    Procedure related complications and radiation exposure to the participants and interventionist were noted in the both arms.

    Time frame: three months

07

Study locations

1 site
  • Department of Nuclear Medicine, PGIMER
    Chandigarh, Chandīgarh 160012, India
08

References and documents

Individual participant data

Plan to share: No — Data generated or analyzed during the study are available from the primary investigator on a valuable and genuine request.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05245630
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Responsible party
Rajender Kumar (Associate Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Feb 18, 2022
Start date
Jul 1, 2020
Primary completion
Dec 31, 2021
Completion
Jan 31, 2022
Last update
Feb 18, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion